- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Addition of Dasatinib to Induction/Consolidation Fails to Boost Survival in Core-Binding Factor AML
June 14th 2025, 6:43pm
European Hematology Association Congress
Dasatinib added to induction and consolidation, then continued as maintenance, did not improve survival in core-binding factor AML.
Talquetamab/Cetrelimab Leads to Deep, Durable Responses in R/R Multiple Myeloma
June 14th 2025, 6:30pm
European Hematology Association Congress
Talquetamab plus cetrelimab showed safety and efficacy in R/R multiple myeloma, including in patients previously treated with bispecific antibodies.
Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant
June 14th 2025, 4:40pm
European Hematology Association Congress
David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.
Dr Ku on the Safety Profile of JNJ-90014496 in Relapsed/Refractory LBCL
June 14th 2025, 11:40am
European Hematology Association Congress
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, discusses safety and efficacy findings with JNJ-90014496 in relapsed/refractory large B-cell lymphoma.
Real-World Data Confirm Efficacy of Axi-Cel Across Patient-Related Factors in R/R LBCL
June 13th 2025, 8:19pm
European Hematology Association Congress
Although age did not affect real-world ORR or EFS with axi-cel in LBCL, an age of 65 years or older and cardiac comorbidities correlated with shorter OS.
Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL
June 13th 2025, 8:10pm
European Hematology Association Congress
Bexobrutideg, a novel BTK degrader, has demonstrated preliminary efficacy and a tolerable safety profile in patients with relapsed/refractory CLL.
Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase
June 13th 2025, 8:05pm
European Hematology Association Congress
ASC4START data support potential for asciminib to be standard of care for newly diagnosed chronic myeloid leukemia in chronic phase.
ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia
June 13th 2025, 7:59pm
European Hematology Association Congress
ESAs or danazol in combination with ruxolitinib displayed similar spleen and symptom outcomes in myelofibrosis with anemia.
JNJ’4496 Shows Preliminary Efficacy and Safety in Relapsed/Refractory LBCL
June 13th 2025, 7:47pm
European Hematology Association Congress
JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.
Ponatinib Is Associated With Improved Survival in Ph+ ALL With MRD Positivity After Induction
June 13th 2025, 7:31pm
European Hematology Association Congress
A post hoc analysis of the PhALLCON study showed response and survival benefits with imatinib in Ph-positive ALL with MRD negativity after induction.
Iptacopan Shows Efficacy Improvements Over Anti-C5 Therapy in Previously Treated Paroxysmal Nocturnal Hemoglobinuria
June 13th 2025, 7:08pm
European Hematology Association Congress
Oral iptacopan monotherapy led to hemoglobin level and transfusion independence benefits vs anti-C5 therapies in paroxysmal nocturnal hemoglobinuria.
Cyclosporin Plus Cyclophosphamide Outperforms SOC Therapy in GVHD Prevention
June 13th 2025, 6:24pm
European Hematology Association Congress
Cyclosporin/cyclophosphamide after allogeneic stem cell transplant improved outcomes vs cyclosporin/methotrexate in high-risk hematologic malignancies.
Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML
June 13th 2025, 5:20pm
European Hematology Association Congress
Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.
Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS
June 13th 2025, 4:40pm
European Hematology Association Congress
Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.
Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma
June 13th 2025, 4:30pm
European Hematology Association Congress
Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.
Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo
June 12th 2025, 9:04pm
European Hematology Association Congress
Venetoclax and decitabine-cedazuridine demonstrated complete responses and encouraging survival outcomes in newly diagnosed AML.
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NPM1/KMT2A-Altered AML
June 12th 2025, 9:00pm
European Hematology Association Congress
Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.
Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL
June 12th 2025, 4:16pm
European Hematology Association Congress
Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.
Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma
June 11th 2025, 8:00pm
Sylvester Comprehensive Cancer Center, University of Miami
Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.
EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer
June 10th 2025, 7:52pm
First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.